The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management has raised concerns regarding potential misuse in sports, where effects such as weight loss and enhanced mitochondrial biogenesis may offer performance advantages. In response to these concerns, a study developed detection methods for five GLP-1 receptor agonists, alongside the endogenous metabolite GLP-1(9-36)-NH 2, within serum and dried blood spot (DBS) samples using liquid-chromatography and high-resolution tandem mass spectrometry (LC-HRMS/MS). The aim was to support doping control purposes.
Detection Methodologies
For analytes expected to have low blood concentrations – exenatide, lixisenatide, and GLP-1(9-36)-NH 2 – affinity purification utilizing magnetic beads coupled with anti-GLP-1 antibodies and GLP-1 receptor fusion proteins was employed. This technique achieved limits of detection ranging from 9.4 pg/mL (exenatide) to 48 pg/mL (lixisenatide and GLP-1(9-36)-NH 2 ) in 100 μL of serum. Serum analysis demonstrated superior sensitivity compared to DBS, and was therefore prioritized. For higher-abundant, lipidated peptides – liraglutide, semaglutide, and tirzepatide – mixed-mode anion-exchange solid-phase extraction was utilized. This approach yielded LODs ranging from 0.48 ng/mL (tirzepatide) to 4.7 ng/mL (liraglutide and semaglutide) in serum, and 0.95 ng/mL (liraglutide and semaglutide) to 3.8 ng/mL (tirzepatide) in DBS. Both serum and DBS samples proved suitable for reliable detection.
Validation and Confirmation
Furthermore, the developed methods were validated using post-administration samples from humans treated with semaglutide and tirzepatide, as well as murine samples following administration of exenatide, lixisenatide, and liraglutide, confirming their suitability for sports drug testing.”}